December 20th 2024
The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
The Usefulness of 0.45 µm–Rated Filter Membranes
April 1st 2002In this study, the authors examine the suitability of 0.45 µm–rated filters to be used as sterilizing and bioburden-reduction filters against significant populations of organisms such as B. diminuta in a wide range of differential pressures.
Developing Custom Adhesive Systems for Transdermal Drug Delivery
March 1st 2002Adhesives manufacturers can be involved in the development of transdermal drug delivery products by working with pharmaceutical companies on R&D, materials qualification, manufacturing, and other product development tasks.
Microbial Bioburden on Oral Solid Dosage Forms
February 1st 2002Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.
Filter Integrity Testing in Liquid Applications, Revisited Part II
November 2nd 2001In the concluding part of this article, the authors address diffusive-airflow imprecisions and measurements as well as automated integrity-test equipment, variations in bubble-point measurements, and the identification of a "sterilizing" filter.
From the Formulator to the Tablet Manufacturing Floor: Desiderata and Troubleshooting
October 1st 2001Tablet manufacturers often overlook critical basic concepts or established practices. The author draws from his own experiences and discusses how solid dosage manufacturers can improve production and product quality by optimizing major unit operations.